Status:
COMPLETED
An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer
Lead Sponsor:
Scottsdale Healthcare
Collaborating Sponsors:
National Foundation for Cancer Research
Translational Genomics Research Institute
Conditions:
Advanced Cancer
Eligibility:
All Genders
18+ years
Brief Summary
When a patient with advanced cancer consults with a member of the Phase I drug development team, the investigators utilize all information possible to try to select a therapy for that patient which ha...
Detailed Description
1. To measure the time from biopsy to completion and final analysis of Whole Genome Sequencing (WGS) on patient tumor and non-tumor samples. 2. To examine the frequency with which useable sequence dat...
Eligibility Criteria
Inclusion
- Have a life expectancy of greater than 3 months.
- Patients must have a diagnosis of histologically or cytologically confirmed advanced incurable cancer which has progressed on one or more prior chemotherapeutic, hormonal or biological regimens for advanced disease.
- Be a good medical candidate for and willing to undergo a biopsy or surgical procedure to obtain tissue, which may or may not be part of the patient's routine care for their malignancy.
Exclusion
- Patients with symptomatic CNS metastasis.
- Known HIV, HBV or HCV infection requiring antiviral therapy.
- Pregnant or breast-feeding patients or any patient with childbearing potential not using adequate contraception.
- Inaccessible tumor for biopsy
Key Trial Info
Start Date :
September 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01443390
Start Date
September 1 2011
End Date
March 1 2013
Last Update
May 14 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare
Scottsdale, Arizona, United States, 85258